clinical trial · NCT06727396
A Study to Investigate the Safety, Tolerability, PK, and PD of CKD-508 in Healthy Participants
Healthy SubjectsCKD-508 TabletPlacebo Tablet
brief summary
This Phase 1, randomized, parallel-group, placebo-controlled, double-blinded study aims to evaluate the safety, PK, and PD of CKD-508 when administered multiple times once daily to healthy participants.
started
Nov 14, 2024
primary completion
Jun 5, 2025
completion
Jun 5, 2025
last updated
Feb 27, 2026
official title
A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, Single Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CKD-508 in Healthy Participants.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol